Pawan Bhatnagar, MD
Retina Specialist · Slingerlands, NYNPI 1821057233
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 38.8% of the total. Reporting peaked in 2024 at $50 and has fallen 72.1% since, to $14 in 2025. That places this record below the midpoint for retina specialist clinicians in NY, where the typical reported total is $2,298.
Across 5 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$41
- Alcon$35
- Alimera Sciences, Inc.$16
- Amgen$14
Across 2 payments — averaging $6815.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$14K
What the payments were for
- Food & beverage$106100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 2 | $41 |
| Alcon | 1 | $35 |
| Alimera Sciences, Inc. | 1 | $16 |
| Amgen | 1 | $14 |
How this compares
$106 in reported general payments places this provider in the 0th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 243 | $52,746 |
| IlevroNepafenac | 26 | $13,075 |
| Prednisolone Acetate | 171 | $10,884 |
| ProlensaBromfenac Sodium | 24 | $9,153 |
| Difluprednate | 59 | $7,069 |
| Brimonidine Tartrate | 64 | $3,069 |
| Loteprednol Etabonate | 11 | $2,224 |
| Ketorolac Tromethamine | 94 | $2,149 |
| Atropine Sulfate | 34 | $1,593 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 65 | $1,259 |
| Ofloxacin | 50 | $1,040 |
| Dorzolamide Hcl | 38 | $729 |
| Latanoprost | 53 | $557 |
| Timolol Maleate | 34 | $471 |
| ErythromycinErythromycin Base | 22 | $259 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Slingerlands
- Spencer LangevinSlingerlands$2K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.